At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
EXPAREL 20 mL +1 moredrug
Likely dose
EXPAREL 20 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Safety and Efficacy of EXPAREL When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) for Prolonged Postsurgical Analgesia in Subjects Undergoing Robot-assisted Laparoscopic Prostatectomy
In Brief
A Phase 4 clinical trial evaluating EXPAREL 20 mL and EXPAREL 40 mL for Postsurgical Pain and 2 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of the study is to assess the safety and efficacy of EXPAREL when administered via infiltration into the transversus abdominis plane (TAP) to prolonged postsurgical analgesia in men undergoing robot-assisted laparoscopic prostatectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostsurgical Pain, Analgesia, Prostatectomy
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2012
First PostedApr 2012
Primary CompletionMay 2012
Study CompletionJul 2012
TodayJul 2026
First PostedApr 20, 2012
Enrollment StartMar 1, 2012
Primary CompletionMay 1, 2012
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 14.2 years ago
Interventions
EXPAREL 20 mLdrug
EXPAREL 266 mg (undiluted)
EXPAREL 40 mLdrug
EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.